1. HLTF resolves G4s and promotes G4-induced replication fork slowing to maintain genome stability.
- Author
-
Bai G, Endres T, Kühbacher U, Mengoli V, Greer BH, Peacock EM, Newton MD, Stanage T, Dello Stritto MR, Lungu R, Crossley MP, Sathirachinda A, Cortez D, Boulton SJ, Cejka P, Eichman BF, and Cimprich KA
- Subjects
- Humans, Telomere Homeostasis, DNA Damage, HEK293 Cells, Multifunctional Enzymes metabolism, Multifunctional Enzymes genetics, DNA-Directed DNA Polymerase, Genomic Instability, DNA Replication, G-Quadruplexes, Transcription Factors metabolism, Transcription Factors genetics, DNA-Binding Proteins metabolism, DNA-Binding Proteins genetics, MutS Homolog 2 Protein metabolism, MutS Homolog 2 Protein genetics, DNA Primase metabolism, DNA Primase genetics
- Abstract
G-quadruplexes (G4s) form throughout the genome and influence important cellular processes. Their deregulation can challenge DNA replication fork progression and threaten genome stability. Here, we demonstrate an unexpected role for the double-stranded DNA (dsDNA) translocase helicase-like transcription factor (HLTF) in responding to G4s. We show that HLTF, which is enriched at G4s in the human genome, can directly unfold G4s in vitro and uses this ATP-dependent translocase function to suppress G4 accumulation throughout the cell cycle. Additionally, MSH2 (a component of MutS heterodimers that bind G4s) and HLTF act synergistically to suppress G4 accumulation, restrict alternative lengthening of telomeres, and promote resistance to G4-stabilizing drugs. In a discrete but complementary role, HLTF restrains DNA synthesis when G4s are stabilized by suppressing primase-polymerase (PrimPol)-dependent repriming. Together, the distinct roles of HLTF in the G4 response prevent DNA damage and potentially mutagenic replication to safeguard genome stability., Competing Interests: Declaration of interests K.A.C. is a member of the scientific advisory board of IDEAYA Biosciences and RADD Pharmaceuticals and is on the oncology advisory board for GlaxoSmithKline. S.J.B. is a co-founder, VP Science Strategy and shareholder at Artios Pharma Ltd. K.A.C. and S.J.B. are also members of the advisory board at Molecular Cell., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF